JP7803925B2 - 抗トランスフェリン受容体(TfR)抗体およびその使用 - Google Patents

抗トランスフェリン受容体(TfR)抗体およびその使用

Info

Publication number
JP7803925B2
JP7803925B2 JP2023504620A JP2023504620A JP7803925B2 JP 7803925 B2 JP7803925 B2 JP 7803925B2 JP 2023504620 A JP2023504620 A JP 2023504620A JP 2023504620 A JP2023504620 A JP 2023504620A JP 7803925 B2 JP7803925 B2 JP 7803925B2
Authority
JP
Japan
Prior art keywords
seq
antibody
amino acid
acid sequence
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023504620A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023535443A5 (cg-RX-API-DMAC7.html
JP2023535443A (ja
Inventor
サブラマニアン,ロメシュ,アール.
カタナニ,モハマド,ティー.
ウィーデン,ティモシー
デジャルダン,コディ,エー.
クイン,ブレンダン
ナジム,ジョン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dyne Therapeutics Inc
Original Assignee
Dyne Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyne Therapeutics Inc filed Critical Dyne Therapeutics Inc
Publication of JP2023535443A publication Critical patent/JP2023535443A/ja
Publication of JP2023535443A5 publication Critical patent/JP2023535443A5/ja
Priority to JP2026002189A priority Critical patent/JP2026077638A/ja
Application granted granted Critical
Publication of JP7803925B2 publication Critical patent/JP7803925B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2023504620A 2020-07-23 2021-07-09 抗トランスフェリン受容体(TfR)抗体およびその使用 Active JP7803925B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026002189A JP2026077638A (ja) 2020-07-23 2026-01-08 抗トランスフェリン受容体(TfR)抗体およびその使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063055721P 2020-07-23 2020-07-23
US63/055,721 2020-07-23
US202063069071P 2020-08-23 2020-08-23
US63/069,071 2020-08-23
US202163143825P 2021-01-30 2021-01-30
US63/143,825 2021-01-30
PCT/US2021/040984 WO2022020105A1 (en) 2020-07-23 2021-07-09 Anti-transferrin receptor (tfr) antibody and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026002189A Division JP2026077638A (ja) 2020-07-23 2026-01-08 抗トランスフェリン受容体(TfR)抗体およびその使用

Publications (3)

Publication Number Publication Date
JP2023535443A JP2023535443A (ja) 2023-08-17
JP2023535443A5 JP2023535443A5 (cg-RX-API-DMAC7.html) 2024-07-17
JP7803925B2 true JP7803925B2 (ja) 2026-01-21

Family

ID=79729848

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023504620A Active JP7803925B2 (ja) 2020-07-23 2021-07-09 抗トランスフェリン受容体(TfR)抗体およびその使用
JP2026002189A Pending JP2026077638A (ja) 2020-07-23 2026-01-08 抗トランスフェリン受容体(TfR)抗体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026002189A Pending JP2026077638A (ja) 2020-07-23 2026-01-08 抗トランスフェリン受容体(TfR)抗体およびその使用

Country Status (11)

Country Link
US (1) US20230256112A1 (cg-RX-API-DMAC7.html)
EP (1) EP4185315A4 (cg-RX-API-DMAC7.html)
JP (2) JP7803925B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230041760A (cg-RX-API-DMAC7.html)
CN (1) CN116348138A (cg-RX-API-DMAC7.html)
AU (1) AU2021312708A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023001005A2 (cg-RX-API-DMAC7.html)
CA (1) CA3186727A1 (cg-RX-API-DMAC7.html)
IL (1) IL299667A (cg-RX-API-DMAC7.html)
MX (1) MX2023000962A (cg-RX-API-DMAC7.html)
WO (1) WO2022020105A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
EP3830259A4 (en) 2018-08-02 2022-05-04 Dyne Therapeutics, Inc. MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
WO2020028832A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2021154477A1 (en) 2020-01-31 2021-08-05 Dyne Therapeutics, Inc. Anti-transferrin receptor (tfr) antibody and uses thereof
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
AU2021313058A1 (en) * 2020-07-23 2023-03-30 Dyne Therapeutics, Inc. Muscle-targeting complexes and uses thereof
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11672872B2 (en) 2021-07-09 2023-06-13 Dyne Therapeutics, Inc. Anti-transferrin receptor antibody and uses thereof
MX2023000984A (es) * 2020-07-23 2023-05-03 Dyne Therapeutics Inc Complejos dirigidos al musculo y usos de los mismos para el tratamiento de distrofinopatias.
WO2023283623A1 (en) 2021-07-09 2023-01-12 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating dystrophinopathies
CA3230796A1 (en) 2021-09-01 2023-03-09 Biogen Ma Inc. Anti-transferrin receptor antibodies and uses thereof
IL316143A (en) 2022-04-15 2024-12-01 Dyne Therapeutics Inc Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
CN120659627A (zh) * 2022-07-29 2025-09-16 瑞泽恩制药公司 用于转铁蛋白受体(tfr)介导的脑和肌肉递送的组合物和方法
US20260015409A1 (en) * 2022-09-20 2026-01-15 Dana-Farber Cancer Institute, Inc. Receptor-mediated endocytosis for targeted internalization and degradation of membrane proteins and cargos
KR20260044219A (ko) 2023-07-21 2026-04-01 매로우 테라퓨틱스, 인크. 조혈 세포 표적화 접합체 및 관련 방법
IL327952A (en) * 2023-10-26 2026-06-01 Biogen Ma Inc Anti-transferrin receptor antibodies and uses thereof
WO2025140522A1 (en) * 2023-12-29 2025-07-03 Nona Biosciences (Suzhou) Co., Ltd. Anti-tfr1 antibodies, preparation methods and uses thereof
CN119192378B (zh) * 2024-10-16 2025-10-17 中国人民解放军军事科学院军事医学研究院 一种pH敏感型人源抗转铁蛋白受体1抗体
CN119161483B (zh) * 2024-10-16 2026-02-06 中国人民解放军军事科学院军事医学研究院 人源抗转铁蛋白受体1抗体及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016208695A1 (ja) 2015-06-24 2016-12-29 Jcrファーマ株式会社 血液脳関門を通過する抗ヒトトランスフェリン受容体抗体
WO2020028836A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle-targeting complexes and uses thereof in treating muscle atrophy
WO2020028842A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating hypertrophic cardiomyopathy
WO2020132584A1 (en) 2018-12-21 2020-06-25 Avidity Biosciences, Inc. Anti-transferrin receptor antibodies and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8734799B2 (en) * 2010-04-13 2014-05-27 The Regents Of The University Of California Unconjugated anti-TfR antibodies and compositions thereof for the treatment of cancer
SG11201509566RA (en) * 2013-05-20 2015-12-30 Genentech Inc Anti-transferrin receptor antibodies and methods of use
FR3049951A1 (fr) * 2016-04-12 2017-10-13 Univ Rabelais Francois Nouvelles constructions peptidiques et leur utilisation dans le traitement de la toxoplasmose
UY38247A (es) * 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016208695A1 (ja) 2015-06-24 2016-12-29 Jcrファーマ株式会社 血液脳関門を通過する抗ヒトトランスフェリン受容体抗体
WO2020028836A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle-targeting complexes and uses thereof in treating muscle atrophy
WO2020028842A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating hypertrophic cardiomyopathy
WO2020132584A1 (en) 2018-12-21 2020-06-25 Avidity Biosciences, Inc. Anti-transferrin receptor antibodies and uses thereof

Also Published As

Publication number Publication date
IL299667A (en) 2023-03-01
MX2023000962A (es) 2023-04-19
CN116348138A (zh) 2023-06-27
US20230256112A1 (en) 2023-08-17
WO2022020105A1 (en) 2022-01-27
AU2021312708A1 (en) 2023-03-16
EP4185315A1 (en) 2023-05-31
EP4185315A4 (en) 2024-07-31
KR20230041760A (ko) 2023-03-24
CA3186727A1 (en) 2022-01-27
JP2026077638A (ja) 2026-05-13
BR112023001005A2 (pt) 2023-03-28
JP2023535443A (ja) 2023-08-17

Similar Documents

Publication Publication Date Title
JP7807379B2 (ja) 抗トランスフェリン受容体(tfr)抗体およびその使用
JP2026077638A (ja) 抗トランスフェリン受容体(TfR)抗体およびその使用
US11672872B2 (en) Anti-transferrin receptor antibody and uses thereof
US12624120B2 (en) Anti-transferrin receptor (TfR) antibody and uses thereof
JP7803926B2 (ja) ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用
JP7780691B2 (ja) ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用
WO2022020109A1 (en) Muscle-targeting complexes and uses thereof in treating muscle atrophy
JP2023535074A (ja) 筋標的化複合体およびそれらの使用
WO2021142313A1 (en) Muscle-targeting complexes and uses thereof
CA3163283A1 (en) Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health
EP4093773A1 (en) Muscle-targeting complexes and uses thereof in treating muscle atrophy
EP4367143A1 (en) Muscle targeting complexes and uses thereof for treating myotonic dystrophy
EA052737B1 (ru) Антитело против рецептора трансферрина (tfr) и его применение
EA053035B1 (ru) Антитело против рецептора трансферрина (tfr) и его применение
EA050686B1 (ru) Мышечно-специфические комплексы и их применение для лечения дистрофинопатий
EA050720B1 (ru) Мышечно-специфические комплексы и их применение для лечения плече-лопаточно-лицевой мышечной дистрофии

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240708

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240708

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250613

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250911

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20250911

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251112

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251210

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260108

R150 Certificate of patent or registration of utility model

Ref document number: 7803925

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150